Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06922188 · ClinicalTrials.gov registry record

Development of Measures to Screen for Financial Hardship in Alzheimer's Disease and Dementia

A clinical trial of Financial Hardship and Alzheimer's Disease (AD), sponsored by Fred Hutchinson Cancer Center.

Recruiting
Registry status
2,460
Enrollment target
1
Study location

NCT06922188: Recruiting study of Financial Hardship and Alzheimer's Disease (AD), sponsored by Fred Hutchinson Cancer Center.

NCT06922188 is a study of Financial Hardship and Alzheimer's Disease (AD) that is actively recruiting participants, run by Fred Hutchinson Cancer Center. The registered enrollment target is 2,460 participants, above the 184-participant average among 5 other Financial Hardship trials with a reported enrollment target (1237% higher). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06922188, a study of Financial Hardship and Alzheimer's Disease (AD), is actively recruiting participants, sponsored by Fred Hutchinson Cancer Center.

RECRUITING
Registry status
2,460 participants
Enrollment target
1
Study location

Study Summary

Alzheimer's Disease and related dementias (AD/ADRD) are common and debilitating conditions. Financial hardship, a multidimensional construct of financial strain, financial stress and asset depletion, is common in AD/ADRD due to exorbitant out-of-pocket spending such as for long-term care, lower work productivity and income for their caregivers that can last for decades after disease onset, and difficulty deciding between nursing home care or home-based care while negotiating insurance coverage. People from historically marginalized groups can experience a double disparity with fewer financial resources to manage AD/ADRD and a greater risk of AD/ADRD. Screening for financial hardship in AD/ADRD is key for addressing the needs of patients and caregivers but critical barriers include a lack of suitable screening measures. Current measures are very general and meant for people without chronic medical conditions or are specific to other diseases. To fill this gap, this study will create a suite of measures that can screen for financial hardship in people with AD/ADRD and their families and caregivers. The measures will include a set to assess caregiver burden; a set to assess patient hardship as reported by the caregiver for patients who cannot report for themselves; and a set of patient-reported measures for patients that are able to report for themselves. To create these financial hardship screening measures, the project will conduct the following aims. Aim 1- Develop financial hardship screening measures for Alzheimer's Disease and related dementias: Using interviews with both caregivers and people with AD/ADRD, key indicators of financial hardship that are unique to AD/ADRD and the point in the lifespan in which it occurs will be identified. The ways that social and caregiver network size affect financial hardship will also be explored. Using the interviews and previous measures, preliminary measures will be created and will be reviewed by experts and a patient and c

Primary Outcome

Qualitative interviews with patients and caregivers will be conducted and analyzed using a framework analysis approach. Interview data will be used to refine our conceptual model of financial hardship (Jones et. al 2024). The unit of measure will be the number of major thematic categories identified through qualitative analysis and the number of conceptual domains established in the finalized model.

Study Locations (1)

Washington

  • Fred Hutchinson Cancer Center - Seattle

Trial Details

FieldValue
Enrollment Target 2,460 participants
Start Date 2025-03-31
Est. Completion 2029-12-18
Fred Hutchinson Cancer Center

483 total trials

What NCT06922188 shows while recruiting

NCT06922188 is an observational study that tracks outcomes without assigning an intervention. Its 2,460 participants enrollment target places it among the larger protocols in the corpus, above the 184-participant average among 5 other Financial Hardship trials with a reported enrollment target (1237% higher).

The record links to 3 conditions, with Financial Hardship appearing as the primary indexed condition, and to 0 interventions.

NCT06922188 reports a single indexed study location in Washington.

Frequently Asked Questions

What is clinical trial NCT06922188 about?

NCT06922188 is a clinical study titled "Development of Measures to Screen for Financial Hardship in Alzheimer's Disease and Dementia". Alzheimer's Disease and related dementias (AD/ADRD) are common and debilitating conditions. Financial hardship, a multidimensional construct of financial strain, financial stress and asset depletion, is common in AD/ADRD due to exorbitant out-of-pocket spending such as for long-term care, lower work...

What is the current status of trial NCT06922188?

This trial is currently recruiting. The enrollment target is 2,460 participants. The study started on 2025-03-31. Estimated completion is 2029-12-18.

What conditions does trial NCT06922188 study?

This clinical trial studies the following conditions: Financial Hardship, Alzheimer's Disease (AD), Alzheimer's Disease and Related Dementia (ADRD).

Who is sponsoring clinical trial NCT06922188?

This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06922188 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Financial Hardship

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT06898593 · 2,448 participants · NA

    Enhancing Engagement by Integrating Goals and Concerns That Matter to Patients

  • NCT06128304 · 2,436 participants · NA

    ACCESS: Accelerating Cervical Cancer Elimination Through the Integration of Screen-and-treat Services

  • NCT06676904 · 2,433 participants · NA

    Neonatal Platelet Transfusion Threshold Trial

  • NCT05345951 · 2,425 participants · NA

    Project e-PBI+ - Parent Intervention to Reduce College Student Drinking and Cannabis Use

Similar registry start date

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

  • NCT07125183 · started 2026-12 · Phase 2

    Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma

  • NCT07292298 · started 2026-11 · Phase 2

    Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates

  • NCT04263285 · started 2026-10 · NA

    Treatment of Depression Post-SCI

Source: ClinicalTrials.gov NCT06922188, the US trial registry maintained by the National Library of Medicine. NCT06922188 (large enrollment · single site footprint · recruiting) retrieved and formatted by PlainTrial, see methodology.